

SOLICITOR

TO: Mail Stop 8
 Director of the U.S. Patent and Trademark Office
 P.O. Box 1450
 Alexandria, VA 22313-1450

**REPORT ON THE
 FILING OR DETERMINATION OF AN
 ACTION REGARDING A PATENT OR
 TRADEMARK**

**OCT 11 2007
 U.S. PATENT & TRADEMARK OFFICE**

In Compliance with 35 § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
 filed in the U.S. District Court Western District of Michigan on the following ☒ Patents or ☐ Trademarks:

DOCKET NO. 1:07-cv-993	DATE FILED 10/2/07	U.S. DISTRICT COURT Western District of Michigan - at Kalamazoo
PLAINTIFF Adams Respiratory Therapeutics, Inc., et al.		DEFENDANT Perrigo Company, et al.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	See attached copy of complaint with exhibits	
2	6,372,252	
3		
4		
5		

In the above—entitled case, the following patent(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK
1	
2	
3	
4	
5	

In the above—entitled case, the following decision has been rendered or judgment issued:

DECISION/JUDGMENT

CLERK RONALD C. WESTON, SR.	(BY) DEPUTY CLERK /s/ Ruth Westcott	DATE 10/9/07
---------------------------------------	---	------------------------

Copy 1—Upon initiation of action, mail this copy to Commissioner Copy 3—Upon termination of action, mail this copy to Commissioner
 Copy 2—Upon filing document adding patent(s), mail this copy to Commissioner Copy 4—Case file copy

**UNITED STATES DISTRICT COURT
FOR THE WESTERN DISTRICT OF MICHIGAN
SOUTHERN DIVISION**

FILED - GR

October 2, 2007 3:37 PM

RONALD C. WESTON, SR., CLERK
U.S. DISTRICT COURT
WESTERN DISTRICT OF MICHIGAN
BY: SW

ADAMS RESPIRATORY THERAPEUTICS,
INC., ADAMS RESPIRATORY OPERATIONS,
INC. and ADAMS RESPIRATORY PRODUCTS,
INC.,

Plaintiffs,

Case No.:

1:07-cv- 993

vs.

HON.

**Richard Alan Enslen
US District Judge**

PERRIGO COMPANY, L. PERRIGO
COMPANY and PERRIGO RESEARCH AND
DEVELOPMENT COMPANY,

Defendants.

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Adams Respiratory Therapeutics, Inc., Adams Respiratory Operations, Inc. and Adams Respiratory Products, Inc. (collectively "Adams"), bring this complaint against Defendants Perrigo Company, L. Perrigo Company and Perrigo Research and Development Company (collectively "Perrigo") and hereby allege as follows:

THE PARTIES

1. Plaintiff Adams Respiratory Therapeutics, Inc. is a corporation incorporated and existing under the laws of the State of Delaware, having its principal place of business at 4 Mill Ridge Lane, Chester, New Jersey 07930.

2. Plaintiff Adams Respiratory Operations, Inc. is a corporation incorporated and existing under the laws of the State of Delaware, having its principal place of business at 14841 Sovereign Road, Fort Worth, Texas 76155.

3. Plaintiff Adams Respiratory Products, Inc. is a corporation incorporated and existing under the laws of the State of Delaware, having its principal place of business at 4 Mill Ridge Lane, Chester, New Jersey 07930.

4. Upon information and belief, Defendant Perrigo Company is a corporation incorporated under the laws of the State of Michigan and having its principal place of business at 515 Eastern Avenue, Allegan, Michigan 49010.

5. Upon information and belief, Defendant L. Perrigo Company is a company incorporated under the laws of the State of Michigan, having a principal place of business at 900 Brooks Avenue, Holland, Michigan 49423.

6. Upon information and belief, Defendant Perrigo Research and Development Company is a corporation incorporated under the laws of the State of Michigan, having its principal places of business at 515 Eastern Avenue, Allegan, Michigan 49010.

7. Upon information and belief, the acts complained of herein were done by, at the direction of, with the authorization, cooperation, participation or assistance of, or least in part for the benefit of Perrigo Company, L. Perrigo Company and Perrigo Research and Development.

JURISDICTION AND VENUE

8. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code. Jurisdiction is based on 28 U.S.C. §§ 1331 and 1338(a).

9. This Court has personal jurisdiction over Perrigo Company, L. Perrigo Company and Perrigo Research and Development at least by virtue of the fact that they conduct business in the State of Michigan, have availed themselves of the rights and benefits of Michigan law, have engaged in substantial and continuing contacts with the State of Michigan, and/or because one or

more are a wholly-owned subsidiary of Perrigo Company, having common officers and directors, and operating as a single-entity.

10. Venue is proper in this Court under 28 U.S.C. §§ 1391(b) and (c) and 28 U.S.C. 1400(b).

FIRST COUNT

11. On April 16, 2002, U.S. Patent No. 6,372,252 ("the '252 Patent") issued.

12. The '252 patent was assigned to Plaintiff Adams Respiratory Operations, Inc., which is a wholly-owned subsidiary of Plaintiff Adams Respiratory Therapeutics, Inc. Plaintiff Adams Respiratory Products, Inc. is the exclusive licensee under the '252 patent. Adams is the owner of the '252 Patent. (A copy of the '252 Patent is attached as **Exhibit 1.**)

13. Adams is the holder of New Drug Application ("NDA") No. 21-282 by which the United States Food and Drug Administration ("FDA") granted approval for 600 mg and 1200 mg extended release tablets including the active ingredient guaifenesin. These tablets are marketed in the United States under the tradename Mucinex®, and are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive.

14. The '252 Patent covers Mucinex® and has been listed in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations ("the Orange Book") for that product.

15. Upon information and belief, Perrigo submitted to the FDA an Abbreviated New Drug Application ("ANDA"), filed under 21 U.S.C. § 355(j), in order to obtain approval to engage in the commercial manufacture, use or sale of guaifenesin extended release tablets prior to the expiration of the '252 Patent. Perrigo's ANDA has been assigned ANDA No. 78-912.

16. Upon information and belief, Perrigo's ANDA No. 78-912 includes a certification with respect to the '252 Patent under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) of the Federal Food, Drug and Cosmetic Act that the '252 Patent is invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo's guaifenesin product.

17. Upon information and belief, Perrigo sent a notice of that certification to Adams on or about August 17, 2007. Adams received a copy of Perrigo's notice letter on or about August 20, 2007.

18. Upon information and belief, the Perrigo product that is the subject of ANDA No. 78-912 will infringe at least one of the '252 Patent claims.

19. Because Perrigo has submitted an ANDA under 21 U.S.C. § 355(j), in order to obtain approval from the FDA to engage in the commercial manufacture, use or sale of a drug product claimed in the '252 Patent before its expiration, Perrigo has committed an act of infringement pursuant to 35 U.S.C. § 271(e)(2)(A).

20. Adams is entitled to relief provided by 35 U.S.C. § 271(e)(4), including an order from this Court that the effective date of the approval of Perrigo's ANDA be a date that is not earlier than the expiration date of the '252 Patent, or any later expiration of exclusivity for the '252 Patent to which Adams is or becomes entitled.

21. Perrigo's certification to the FDA that the '252 Patent was not infringed, invalid and/or unenforceable was baseless, and therefore this case is exceptional under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that the Court enter a Judgment that:

(a) Perrigo infringed one or more claims of the '252 Patent by submitting the aforesaid ANDA;

(b) A permanent injunction be issued, pursuant to 35 U.S.C.


§ 271(e)(4)(B), restraining and enjoining Defendants Perrigo Company, L. Perrigo Company and Perrigo Research and Development Company, their officers, agents, attorneys, and employees, and those acting in privity or concert with them, and their successors and assigns, from engaging in the commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of compositions as claimed in the '252 Patent;

(c) An order be issued pursuant to 35 U.S.C. § 271(e)(4)(A) that the effective date of any approval of Perrigo's ANDA No. 78-912 be a date that is not earlier than the expiration of the '252 Patent, or any later expiration of exclusivity for the '252 Patent to which Plaintiff is or becomes entitled; and

(d) To the extent Perrigo committed any acts with respect to the compositions claimed in the '252 Patent, other than those expressly exempted by 35 U.S.C. § 271(e)(1), Plaintiff be awarded damages for such acts;

(e) Perrigo made a baseless certification to the FDA, which makes this case exceptional under 35 U.S.C. § 285, and Adams therefore is entitled to reasonable attorneys fees; and for such other and further relief as the Court may deem just and proper under the circumstances.

Dated: October 2, 2007



Thomas R. Behm (P40073)
GRUEL, MILLS, NIMS & PLYMAN LLP
50 Monroe Avenue, N.W., Suite 700 West
Grand Rapids, MI 49503
(616) 235-5500

OF COUNSEL:

Dominick A. Conde
John D. Carlin
FITZPATRICK, CELLA,
HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112
(212) 218-2100

Attorneys for Plaintiffs Adams Respiratory
Therapeutics, Inc., Adams Respiratory
Operations, Inc. and Adams Respiratory Products,
Inc.